591 results about "Antibody targeting" patented technology

The invention belongs to the technical field of biological detection, and relates to an antibody composition aiming at pTau217 protein detection and application thereof, and the antibody composition aiming at pTau217 protein detection comprises a target pTau217 protein antibody and a target Tau protein C-terminal antibody. Meanwhile, based on the antibody composition aiming at pTau217 protein detection, the invention further provides a kit for early diagnosis of the Alzheimer's disease. The invention provides an antibody composition aiming at pTau217 protein detection, which is stronger in detection specificity and higher in sensitivity, and an application of the antibody composition.

The invention discloses a specific antibody MR-34 for targeting a coronavirus MERS-CoV spike protein RBD (Radial Basis Disease). The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention contains CDRs with a specific sequence, and can be specifically combined with an MERS-CoV spike protein RBD structural domain. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an MERS-CoV infection detection method.

The invention discloses a bispecific nano antibody targeting CXCL1 and PD-L1 and application thereof, and belongs to the technical field of antibody engineering and bioengineering. The bispecific nano-antibody targeting CXCL1 and PD-L1 comprises at least one nano-antibody for recognizing a target CXCL1 and a nano-antibody for recognizing a target PD-L1, and nano-antibody monomers are connected through a linker. The bispecific nano-antibody targeting PD-L1 / CXCL1 provided by the invention has a unique structure, so that the bispecific nano-antibody targeting PD-L1 / CXCL1 has specific recognition and binding capacities to CXCL1 and PD-L1, the affinity to CXCL1 reaches 1.08 nM, the affinity to PD-L1 reaches 1.09 nM, drug resistance of a patient to antibody treatment caused by immune escape can be effectively prevented, and the bispecific nano-antibody targeting PD-L1 / CXCL1 is suitable for more patients and has good clinical application prospects. And a new thought is provided for CRC treatment.

The invention discloses a shark source nano antibody targeting an FPV-VP2 protein and an application of the shark source nano antibody. The amino acid sequence of the complementarity determining region 3 of the shark source nano antibody is selected from any one of the sequences shown in SEQ ID NO.16 to SEQ ID NO.30, or a sequence having homology with the sequence shown in any one of the sequences shown in SEQ ID NO.16 to SEQ ID NO.30; the amino acid sequence of the shark source nano antibody is selected from any one of the sequences shown in SEQ ID NO.1-SEQ ID NO.15, or the amino acid sequence of the shark source nano antibody is selected from any one of the sequences shown in SEQ ID NO.1-SEQ ID NO.15, or a sequence having homology with the sequence shown in any one of the sequences shown in SEQ ID NO.1-SEQ ID NO.15. The shark source VNAR nano antibody has the advantages of small molecular weight, high affinity, high stability, easiness in genetic engineering modification, low production cost and the like.

The invention discloses an antibody-modified lipid nanoparticle, a preparation method thereof and application of the antibody-modified lipid nanoparticle as a targeting carrier. The invention provides lipid nanoparticles coupled with an antibody and loaded with nucleic acid. The lipid nanoparticles are characterized in that raw materials of the lipid nanoparticles consist of ionizable lipid, phospholipid, steroidal lipid, PEG lipid and PEG-Mal lipid, the PEG lipid is C16-PEG2k, and the PEG-Mal lipid is C16-PEG2k-Mal, and the PEG-Mal lipid is C16-PEG2k-Mal. The method aims at the key scientific problems of low delivery efficiency, insufficient targeting and the like in the field of in-vivo hematopoietic stem / progenitor cell gene therapy at present. The invention develops a lipid nanoparticle delivery system based on antibody modification, provides a modular antibody targeted delivery platform with high universality, and shows huge clinical transformation potential.

The invention belongs to the technical field of biotechnology and animal models, and discloses a double-person-derived mouse model for simulating a tumor immune microenvironment and a construction method and application thereof. The method comprises the following steps: firstly, pretreating NSG immunodeficient mice by adopting low-dose whole-body irradiation in combination with double-antibody targeted bone marrow depletion, and transplanting CD34 + hematopoietic stem cells from the same human donor to complete human immune system reconstruction; separating tumor primary cells, tumor-related fibroblasts and tumor vascular endothelial cells of the same donor, performing three-dimensional co-culture to obtain homologous human tumor organs, and performing in-situ inoculation to immune reconstruction mice to obtain a target model. The core defects of MHC mismatching, low immune reconstruction efficiency, poor tumor immune microenvironment simulation degree, low clinical consistency and the like of an existing model are overcome, and the method can be used for tumor immune treatment drug screening, microenvironment mechanism research and personalized tumor treatment scheme verification.

The invention discloses a Claudin18.2-targeting nano antibody and application thereof, and belongs to the technical field of molecular biology. Aiming at the unique advantages of a nano antibody in the prior art, the invention provides a nano antibody targeting Claudin18.2, the amino acid sequence of the targeting nano antibody is shown as SEQ ID NO.1, and the nano antibody has relatively strong affinity with Claudin18.2 positive cells 293T-Claudin18.2, and can be combined with Claudin18.2 protein expressed on the surfaces of the cells. The targeted Claudin18.2 nano antibody provided by the invention can be prepared through in-vitro engineering bacterium mass expression, can be applied to preparation of protein detection antibodies or therapeutic antibodies, can be used for in-vivo and in-vitro detection of tumor tissues expressed by Claudin18.2, and has important commercial value in clinical disease diagnosis and treatment.

The present disclosure relates to antibodies and antibody fragments specific for CD45. The antibodies are improved humanized versions of murine antibodies. In addition to complex humanization activities, the antibodies are engineered to remove multiple detrimental motifs within the CDR region without losing any beneficial properties. The antibodies are useful for the treatment of diseases associated with CD45.

Provided are a construct targeting 4-1BB and a use thereof. The provided construct comprises an antigen-binding fragment targeting 4-1BB, wherein the amino acid sequence of the heavy chain variable region is as shown in positions 1-114 of SEQ ID No. 3 or positions 126-239 of SEQ ID No. 6, and the amino acid sequence of the light chain variable region is as shown in positions 1-107 of SEQ ID No. 4 or positions 1-107 of SEQ ID No. 6. The construct further comprises an antibody targeting MSLN, forming a bispecific antibody. The provided bispecific antibody has a good T cell activation effect, and also exhibits a good in vitro tumor cell killing effect and in vivo tumor inhibition effect. Thus, the provided bispecific antibody has important significance and application potential for preparing targeted antibody drugs.

The invention relates to a new monoclonal antibody targeting the VP-1 protein of the capsid of the BK polyomavirus, fragments thereof, and uses of same for detecting infection with the BK polyomavirus. The monoclonal antibody is capable of recognizing at least all serotypes Ia, Ib2, II, III and IV of the VP-1 protein of the BK polyomavirus.

The application belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting cross binding of human and cynomolgus monkey CD46 and application thereof. The application utilizes alpaca to generate nanoscale antibodies, the molecular weight of which is about 15 kDa, and the nanoscale antibodies can more efficiently penetrate solid tumor tissues or cross blood-brain barrier, and the binding efficiency of the antibodies and target points is as high as possible. The 11 single-domain antibodies prepared by the application have specificity of anti-human and anti-cynomolgus monkey CD46, and in the binding detection with CD46 target proteins and CD46 overexpression cells, the binding efficiency is significantly better than that of Anti-CD46 humanization antibody, and the single-domain antibodies can be used for tumor treatment. Meanwhile, the single-domain antibodies have cross binding ability of cross species, and can be directly used for preclinical pharmacodynamics and safety evaluation, without the need of developing species-specific alternative antibodies, so that the application achieves 'one target and double effect'.

The invention discloses a nano antibody targeting GPRC5D as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nano antibody is generated by mixed immunization of a GPRC5D polypeptide antigen with a sequence shown as SEQ ID NO: 1 and a GPRC5D protein antigen with a sequence shown as SEQ ID NO: 2. The preparation method comprises the following steps: mixing the GPRC5D polypeptide antigen and the GPRC5D protein antigen to immunize alpaca, sampling blood, constructing an antibody library, screening a phage display antibody library, expressing protein, and selecting the nano antibody with the highest affinity. The invention further provides a radionuclide labeled molecular probe, the nano antibody is small in molecular weight and can recognize a large number of epitopes, and the molecular probe prepared from the nano antibody can obtain high-quality images, is used for preparing products for developing multiple myeloma or detecting GPRC5D expression level and has wide application prospects.

The present disclosure provides an antibody or antigen binding fragment thereof targeting c-MET, an antibody drug conjugate and use thereof in the treatment of cancer. The disclosure also provides nucleotides encoding the c-MET antibody or the antigen-binding fragment thereof, a polynucleotide combination, an expression vector and an expression vector combination, a pharmaceutical composition comprising the c-MET antibody or the antigen-binding fragment thereof, an antibody drug conjugate, and applications thereof in the preparation of drugs for treating or preventing cancers.

The invention belongs to the technical field of molecular biology, and particularly discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The nano antibody can be specifically combined with a B cell antigen epitope of bovine TLR7 protein, and the B cell antigen epitope is selected from SEQ ID NO: 1 and / or SEQ ID NO: 2. The invention discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The specific nano antibody targeting bovine TLR7 protein is high in stability and specificity and has super-strong affinity.

The invention relates to a nano antibody targeting CD117 and application of the nano antibody. The invention also relates to a CD117-targeting antibody or an antigen binding fragment thereof and an application of the CD117-targeting antibody or the antigen binding fragment thereof.

The invention relates to the technical field of biological medicines, in particular to a CKAP4-targeted tumor antigen peptide, a vaccine and application of the CKAP4-targeted tumor antigen peptide. The invention provides a high-immunogenicity tumor antigen peptide RLTELTKSI targeting human and mouse homologous CKAP4 protein, and the tumor antigen peptide and a vaccine thereof can realize efficient killing of CKAP4 positive tumor cells and remarkable inhibition of CT26 subcutaneous tumor by activating specific CD8 + T cell immune response. The traditional single-target limitation is broken through, the co-expression characteristic of CKAP4 in tumor cells and immunosuppressive cells (TAM / TAN) is utilized, a double-target and double-channel mechanism is initiated, and the immunosuppressive state of cold tumors is effectively reversed by inducing T cells to synchronously kill tumor cells and remodel an immune microenvironment. According to the technology, CKAP4 is expanded from an antibody target to a T cell vaccine target, lasting specific CTL response can be stimulated, the off-target risk of antibody treatment is avoided, a universal treatment scheme can be provided for solid tumors, and the clinical transformation potential and the treatment broad spectrum are remarkably improved.

Provided in the present invention are a single-domain antibody targeting TfR1 and the use thereof. Specifically, provided in the present invention are a corresponding anti-TfR1 antibody, a chimeric antigen receptor, a fusion protein, a recombinant protein and a coding nucleic acid thereof, an expression vector, a host cell, etc. In addition, an anti-TfR1 single-domain antibody-PMO conjugate is prepared. The single-domain antibody has properties such as binding activity and stability, and can be used for tumor therapy and immunodetection.

The invention discloses a TL1A targeting antibody and an application thereof. The antibody provided by the invention can be used for blocking the interaction between TL1A and DR3, is helpful to achieve the purpose of intervention from the early stage of inflammation, inhibits immune cells such as effector T cells from releasing cytokines for proinflammatory reaction, and provides more possibilities for treatment methods of IBD patients or other TL1A related diseases.

The invention relates to a monoclonal antibody targeting RSV F protein, and a related product and application thereof. The monoclonal antibody (AD5) or the antigen binding fragment of the monoclonal antibody is specifically bound with the Site III antigen epitope of the RSV F protein. The antibody AD5 disclosed by the invention has the characteristics of targeting high-conservative epitope (Site III) and having high neutralizing activity, and overcomes the main defect that the neutralizing activity is not high when the existing listed antibody targets the high-conservative epitope.

Disclosed are an antibody targeting IL-31RA or an antigen-binding fragment thereof and a use thereof. The antibody or the antigen-binding fragment thereof provided by the present invention can specifically bind to IL-31RA, and competitively inhibit the downstream signal pathway mediated by cytokine IL-31, effectively reducing the inflammatory response; and a pharmaceutical composition containing an anti-IL-31RA antibody can be used for treating or preventing atopic dermatitis, pruritus, prurigo nodularis, or systemic sclerosis.

The invention belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting cross binding of human and cynomolgus monkey CD46 and application of the single-domain antibody. The alpaca is utilized to generate the nanoscale antibody, the molecular weight of the nanoscale antibody is about 15 kDa, the nanoscale antibody can more efficiently penetrate solid tumor tissues or cross a blood brain barrier, and the binding efficiency of the antibody and a target spot is improved as much as possible. The 11 single-domain antibodies prepared by the invention have the specificity of resisting human and cynomolgus monkey CD46, the binding potency of the 11 single-domain antibodies is remarkably superior to that of an Anti-CD46 humanization antibody in the binding detection of CD46 target protein and CD46 overexpression cells, and the 11 single-domain antibodies can be used for treating tumors. Meanwhile, the single-domain antibody disclosed by the invention has cross-species cross binding capacity, can be directly used for preclinical pharmacodynamics and safety evaluation, does not need to develop a species-specific substitution antibody, and realizes'one target and double effects'.

CD318 (CDCP1) is a CUB-domain containing cell surface protein over-expressed in major types of cancers to promote tumor growth and metastasis. The present disclosure relates to the identification and characterization of novel anti-CD318 monoclonal antibodies. By targeting CD318 as a tumor associated antigen, the disclosure further relates to different modalities of using anti-CD318 antibodies to kill cancer cells, including CD318 antibody based immunocytokines, CD318 antibody-based immune modulators, and CD318 antibody drug conjugates.

The invention belongs to the technical field of biological medicine, and provides an antibody targeting Gn glycoprotein on the surface of a severe fever with thrombocytopenia syndrome virus and application of the antibody. The antibodies N2C1 and N2D2 and the bispecific antibody obtained by modification based on the antibodies N2C1 and N2D2 provided by the invention can be specifically combined with Gn glycoprotein on the surface of the severe fever with thrombocytopenia syndrome virus, and show a strong neutralization protection effect in in-vitro cell and in-vivo animal experiments. Therefore, the N2C1 and N2D2 antibodies and the bispecific antibody obtained by modification can be used as drugs for preventing or treating severe fever with thrombocytopenia syndrome virus infection.

The present invention relates to a novel antibody targeting B7-H3 or an antigen-binding fragment thereof, a chimeric antigen receptor (CAR) comprising same, an immune cell comprising the CAR, and uses thereof. The CAR-T cells according to the present invention have low toxicity and excellent antitumor activity, and thus can be effectively used in immune cell treatment for cancer treatment.

Embodiments described herein relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, and pomalidomide, to the subject to treat the multiple myeloma.

The present invention relates to an antibody targeting ActRIIB and an application thereof. Specifically, the invention provides an ActRIIB binding molecule, which comprises a heavy chain variable region containing CDR1, CDR2 and CDR3, and has the function of identifying and binding ActRIIB. The antibody can reduce animal fat content and / or increase animal muscle content.

The invention provides an antibody targeting synergistic MMP intelligent response drug delivery system as well as a preparation method and application thereof. Based on the characteristics of a tumor microenvironment, a B7H3 targeting / MMP responsive drug delivery system is constructed, a B7H3 targeting antibody is modified to actively target a tumor cell surface antigen B7H3 to be combined with the B7H3 targeting antibody, the enrichment degree of a nano-drug in a tumor focus is improved through precise targeting, and the drug delivery efficiency is improved. Further, under the action of matrix metalloproteinase with high specificity expression in a tumor microenvironment, the designed and screened intelligent responsive polypeptide is subjected to enzymolysis to break so as to expose cationic groups, so that charge overturning of the nano-drug is promoted, and the stable nano-drug with negative charges in a physiological blood circulation system is converted into a nano-drug with positive charges; the medicine is endowed with the capacity of deeply penetrating into solid tumors, the treatment effect of the medicine on tumors is improved by breaking through a matrix barrier, and a new method is provided for treating solid tumors represented by pancreatic cancer.

The invention discloses a nano antibody of a targeted ubiquitin ligase RNF149 and an application of the nano antibody of the targeted ubiquitin ligase RNF149. The nano antibody is composed of a heavy chain variable region containing CDR1, CDR2 and / or CDR3, the CDR1 comprises an amino acid sequence as shown in SEQ ID NO: 4, 8 or 12, the CDR2 comprises an amino acid sequence as shown in SEQ ID NO: 5, 9 or 13, and the CDR3 comprises an amino acid sequence as shown in SEQ ID NO: 6, 10 or 14. The humanized nano antibody of the targeted ubiquitin ligase RNF149, provided by the invention, has relatively high affinity with RNF149 extracellular domain protein, and can be used for detecting the RNF149 and carrying out related researches.

The invention relates to an antibody or an antigen fragment of a targeted human CD7 and application of the antibody or the antigen fragment. The antibody and the CD7-CAR based on the antibody fragment have extremely strong affinity with a CD7 antigen molecule, and a blocking molecule containing the antibody can almost completely block the expression of the CD7 molecule on the cell surface without influencing the normal amplification of T cells, so that the self-killing of the CD7-CAR-T cells can be effectively avoided. The CD7-CAR-T cell constructed on the basis of the single-domain antibody of the targeted human source CD7 has a strong killing effect on a target cell.

Disclosed herein are compositions and uses of tumor activated antibodies targeting EGFR and effector cell antigens. In particular, the present application provides isolated recombinant polypeptide complexes that comprise binding domains that selectively bind to an effector cell antigen and EGFR, in which one or more of the binding domains is selectively activated in the tumor microenvironment and the isolated polypeptide or polypeptide complex comprises a half-life extending molecule.